A non-opioid drug for pain developed by UK biotech Levicept, with a new mechanism of action, has shown it can reduce pain associated with osteoarthritis in a phase 2 trial.

BioMarin's decision comes as the first potential competition for Roctavian is getting closer to the market. Last month, Pfizer and Sangamo reported phase 3 results with their haemophilia A gene ...

Symbiotic Capital – which starts life with more than $600 million at its disposal, is an affiliate of Bellco Capital, an ...

Chronic cough impacts up to 10% of the adult population and has a physical, psychological, and social impact on patients’ ...

The solid quarter is important for Bayer as it tries to rebuild under chief executive Bill Anderson, who was brought in to ...

This approach not only aligns companies with cutting-edge scientific advancements, but also builds investor confidence by ...

The latest lawsuit brought by the family of Henrietta Lacks, filed in a federal court in Maryland, names Novartis Pharma, ...

Bristol-Myers Squibb has handed back rights to a TIGIT drug partnered with Agenus, ending an alliance that could have been worth up to $1.56 billion to the biotech.

Our fourth Changing Faces round-up is one that we don’t always publish, but in May and June we heard about enough hires in ...

Ireland-headquartered pharma group Mallinckrodt has agreed to divest its subsidiary Therakos to private equity firm CVC ...

Shares in Actinium Pharmaceuticals have lost almost two-thirds of their value after the FDA asked for a second clinical trial ...

Virtual and augmented reality tools have reached a level of maturity to be utilised across various industries. In this article, Ben Hargreaves asks whether there is particular potential for the ...